We'll Be in a Solid Place Entering 2019, Says Novartis' CEO

The transcript discusses the company's strong earnings and raised sales guidance, driven by growth in innovative medicines and oncology. It highlights the acquisition of Endocyte, expected to enhance the company's oncology portfolio with potential blockbuster treatments. The company anticipates solid returns from this investment. Pricing strategies and transparency are addressed, emphasizing patient affordability and value-based pricing. Cost management efforts focus on streamlining manufacturing and business services. Future acquisitions aim to strengthen core therapeutic areas, including oncology and gene therapy.

What factors contributed to the strong momentum in the innovative medicines business?

What is the significance of the deal with Endocyte in the context of cancer treatment?

What are the expected outcomes of the $2.1 billion deal mentioned in the text?

How does the company plan to ensure patient affordability for their medicines?

What role do stakeholders play in the pricing and affordability of medicines?

What strategies are being implemented to cut costs in the manufacturing sector?

What are the company's future plans regarding acquisitions in the oncology sector?